The American Cancer Society’s Breast Cancer Facts and Figures 2017 to 2018:
- 252,710 new cases of invasive breast cancer will be diagnosed among women
and 470 cases will be diagnosed in men. In addition, 63,410 cases of in
situ breast carcinoma will be diagnosed among women. Approximately 40,610
women and 460 men are expected to die.
- In January 2016, more than 3.5 million U.S. women with a history of breast
cancer were alive. Some of these women were cancer-free, while others
still had evidence of cancer and may have been undergoing treatment.
Female breast cancer survival rates after diagnosis as of 2017:
91% after 5 years
86% after 10 years
80% after 15 years
- MALE BREAST CANCER is rare. Men are usually diagnosed with advanced-staged
breast cancer due to decreased awareness and delayed detection because
screening mammography is not recommended for men.
Some local county facts:
Female Breast Cancer from 2011 to 2015
As reported by
King George County
How is MWH helping in the fight against breast cancer?
MWHC Regional Cancer Center (RCC) has begun a Breast Microseed Treatment
program using technology and techniques from Concure Oncology®/Breast
Microseed Inc. RCC is first in the Washington, DC, metro area to offer
this one-time, one-hour radiation treatment option.
What is Breast Microseed Treatment?
Breast Microseed Treatment® (BMT) is a ground-breaking method of radiation
therapy for women with early-stage breast cancer after a lumpectomy, by
using brachytherapy. BMT has proven to be an effective type of breast
cancer radiation in treating early stage cancers, while offering patients
a simpler, more convenient, less painful and less costly treatment option.
BMT involves the precise placement of radioactive seeds (palladium Pd-103
sources) that are permanently implanted in the affected breast. The seeds
slowly release the prescribed dose overtime.
CONCURE Breast Microseed Key Highlights:
- One-time radiation more convenient for the patient and family care. Fewer
- Low Dose Radiation (LDR) Brachytherapy for breast cancer, already proven
in prostate cancer and successfully adapted.
- Published five-year outcomes demonstrated effectiveness compared to external
beam radiation therapy.
- FDA-cleared device, ultrasound-guided procedure.
- Inclusion in the national patient registry.
- Reduction in side effects, risk of infection, and damage to heathy tissue.
98% patient satisfaction
96.4% 5-year disease-free survival
7.4% 5-year overall survival
97% rated good or excellent cosmesis
1.2% observed local recurrence
Breast Microseed Treatment Eligibility:
- Confirmed histological diagnosis of invasive ductal carcinoma or ductal
carcinoma in situ (DCIS).
- Age is greater than 50 years old
- Maximum tumor size is 3 cm
- Surgical margins clear for DCIS. Margin clear by greater than or equal to 2 mm.
- Nodal Status, Macroscopically or microscopically pNO (i+ accepted)
- The seroma must be defined with CT and Ultrasound. Seroma sizes less then
a2.5 cm along planned needle insertion direction.
Why is there a need for a Breast Microseed Research Registry?
Further research is still needed to evaluate the safety of this procedure
and to detect serious adverse events. A registry represents a unique opportunity
to ensure adequate training of physicians performing the procedure as
well as capture long term outcomes.
MWHC Research Dept is collecting data for this Multicenter Registry Study
of Breast Microseed Treatment for Early Stage Breast Cancer. Research
Registry collection of data after enrollment includes collection of data
from post dosimetry radiation reports, 2-month follow-up questionnaires,
and yearly questionnaires for a total of 10 years after having the procedure.
John Chinault, MD is the Principle Investigator for this clinical research registry.
Please contact firstname.lastname@example.org for more information.